119 related articles for article (PubMed ID: 33883484)
21. 68Ga/64Cu PSMA Bio-Distribution in Prostate Cancer Patients: Potential Pitfalls for Different Tracers.
Calabria F; Pichler R; Leporace M; Wolfsgruber J; Coscarelli P; Dunzinger A; Schillaci O; Cascini GL; Bagnato A
Curr Radiopharm; 2019; 12(3):238-246. PubMed ID: 31113354
[TBL] [Abstract][Full Text] [Related]
22. Positron Emission Tomography Imaging of Programmed Death 1 Expression in Cancer Patients Using 124I-Labeled Toripalimab: A Pilot Clinical Translation Study.
Wang S; Zhu H; Ding J; Wang F; Meng X; Ding L; Zhang Y; Li N; Yao S; Sheng X; Yang Z
Clin Nucl Med; 2021 May; 46(5):382-388. PubMed ID: 33512952
[TBL] [Abstract][Full Text] [Related]
23. SUV
Baiocco S; Matteucci F; Mezzenga E; Caroli P; Di Iorio V; Cittanti C; Bevilacqua A; Paganelli G; Sarnelli A
Mol Imaging Biol; 2020 Aug; 22(4):1070-1077. PubMed ID: 31758510
[TBL] [Abstract][Full Text] [Related]
24. Combined Utility of
Kalapara AA; Ballok ZE; Ramdave S; O'Sullivan R; Ryan A; Konety B; Grummet JP; Frydenberg M
Eur Urol Oncol; 2022 Jun; 5(3):314-320. PubMed ID: 33741337
[TBL] [Abstract][Full Text] [Related]
25. Standardised uptake values as determined on prostate-specific membrane antigen positron emission tomography/computed tomography is associated with oncological outcomes in patients with prostate cancer.
Bodar YJL; Veerman H; Meijer D; de Bie K; van Leeuwen PJ; Donswijk ML; van Moorselaar RJA; Hendrikse NH; Boellaard R; Oprea-Lager DE; Vis AN
BJU Int; 2022 Jun; 129(6):768-776. PubMed ID: 35166426
[TBL] [Abstract][Full Text] [Related]
26. Comparison of [
Uprimny C; Svirydenka A; Fritz J; Kroiss AS; Nilica B; Decristoforo C; Haubner R; von Guggenberg E; Buxbaum S; Horninger W; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1873-1883. PubMed ID: 29766246
[TBL] [Abstract][Full Text] [Related]
27. Dual-phase (18)F-fluorocholine PET/CT to detect locoregional recurrence of prostate cancer: comparison between each time point of imaging and a summation scan.
Tong AK; Zhang ZX; Zaheer S; Yan XS
Clin Imaging; 2016; 40(3):486-91. PubMed ID: 27133692
[TBL] [Abstract][Full Text] [Related]
28. Comparison of
Schollhammer R; Robert G; Asselineau J; Yacoub M; Vimont D; Balamoutoff N; Bladou F; Bénard A; Hindié E; Gallerande HC; Morgat C
J Nucl Med; 2023 Mar; 64(3):379-385. PubMed ID: 36215569
[TBL] [Abstract][Full Text] [Related]
29. Clinical Translation and First In-Human Use of [
Eppard E; de la Fuente A; Benešová M; Khawar A; Bundschuh RA; Gärtner FC; Kreppel B; Kopka K; Essler M; Rösch F
Theranostics; 2017; 7(18):4359-4369. PubMed ID: 29158832
[TBL] [Abstract][Full Text] [Related]
30. Usefulness of PET/CT 18-FDG for the diagnosis and follow-up of urological, urothelial and kidney tumours.
González-Ruiz de León C; García-Rodríguez J; Pérez-Castro N; Vigil-Díaz C; Pérez-Haro ML; Fernández-Gómez JM
Actas Urol Esp (Engl Ed); 2019; 43(1):32-38. PubMed ID: 30100141
[TBL] [Abstract][Full Text] [Related]
31. Value of
Beheshti M; Taimen P; Kemppainen J; Jambor I; Müller A; Loidl W; Kähkönen E; Käkelä M; Berndt M; Stephens AW; Minn H; Langsteger W
Eur Radiol; 2023 Jan; 33(1):472-482. PubMed ID: 35864350
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic utility of metabolic parameters on FDG PET/CT for lymph node metastasis in patients with cN2 non-small cell lung cancer.
Nakanishi K; Nakamura S; Sugiyama T; Kadomatsu Y; Ueno H; Goto M; Ozeki N; Fukui T; Iwano S; Chen-Yoshikawa TF
BMC Cancer; 2021 Sep; 21(1):983. PubMed ID: 34474680
[TBL] [Abstract][Full Text] [Related]
33. A microdose clinical trial to evaluate [
Lee I; Lim I; Byun BH; Kim BI; Choi CW; Woo SK; Lee KC; Kang JH; Kil HS; Park C; Chi DY; Park J; Song K; Lim SM
Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):95-102. PubMed ID: 32458006
[TBL] [Abstract][Full Text] [Related]
34. Imaging of Brain Tumors with Copper-64 Chloride: Early Experience and Results.
Panichelli P; Villano C; Cistaro A; Bruno A; Barbato F; Piccardo A; Duatti A
Cancer Biother Radiopharm; 2016 Jun; 31(5):159-67. PubMed ID: 27228278
[TBL] [Abstract][Full Text] [Related]
35. Liver metastases from prostate cancer at 11C-Choline PET/CT: a multicenter, retrospective analysis.
Ghedini P; Bossert I; Zanoni L; Ceci F; Graziani T; Castellucci P; Ambrosini V; Massari F; Nobili E; Melotti B; Musto A; Zoboli S; Antunovic L; Kirienko M; Chiti A; Mosconi C; Ardizzoni A; Golfieri R; Fanti S; Nanni C
Eur J Nucl Med Mol Imaging; 2018 May; 45(5):751-758. PubMed ID: 29192364
[TBL] [Abstract][Full Text] [Related]
36. Lymph node staging with 68Ga-PSMA PET in patients with intermediate and high-risk prostate cancer suitable for radical prostatectomy managed in a prostate cancer unit.
Maestroni UV; Campobasso D; Guarino G; Acampora A; Scarlattei M; Ziglioli F; Dinale F; Baldari G; Migliari S; Gasparro D; Ferretti S; Silini EM; Ruffini L
Chin Clin Oncol; 2023 Jun; 12(3):22. PubMed ID: 37417288
[TBL] [Abstract][Full Text] [Related]
37.
Delpassand ES; Ranganathan D; Wagh N; Shafie A; Gaber A; Abbasi A; Kjaer A; Tworowska I; Núñez R
J Nucl Med; 2020 Jun; 61(6):890-896. PubMed ID: 31924723
[TBL] [Abstract][Full Text] [Related]
38. Radiation Dosimetry and Biodistribution of
Meyer C; Dahlbom M; Lindner T; Vauclin S; Mona C; Slavik R; Czernin J; Haberkorn U; Calais J
J Nucl Med; 2020 Aug; 61(8):1171-1177. PubMed ID: 31836685
[TBL] [Abstract][Full Text] [Related]
39.
Wong K; Sheehan-Dare G; Nguyen A; Ho B; Liu V; Lee J; Brown L; Dear R; Chan L; Sharma S; Malaroda A; Smith I; Lim E; Emmett L
Pharmaceuticals (Basel); 2022 Jun; 15(7):. PubMed ID: 35890071
[TBL] [Abstract][Full Text] [Related]
40. Normal distribution pattern and physiological variants of 68Ga-PSMA-11 PET/CT imaging.
Demirci E; Sahin OE; Ocak M; Akovali B; Nematyazar J; Kabasakal L
Nucl Med Commun; 2016 Nov; 37(11):1169-79. PubMed ID: 27333090
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
